First Time Loading...

Taro Pharmaceutical Industries Ltd
NYSE:TARO

Watchlist Manager
Taro Pharmaceutical Industries Ltd Logo
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Watchlist
Price: 42.4 USD -0.19% Market Closed
Updated: Apr 28, 2024
Section:
 

Wall Street
Price Targets

TARO Price Targets Summary
Taro Pharmaceutical Industries Ltd

Wall Street analysts forecast TARO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TARO is 43.86 USD with a low forecast of 43.43 USD and a high forecast of 45.15 USD.

TARO Lowest Forecast
Wall Street Target
43.43 USD
2% Upside
TARO Average Forecast
Wall Street Target
43.86 USD
3% Upside
TARO Highest Forecast
Wall Street Target
45.15 USD
6% Upside
Lowest
Price Target
43.43 USD
2% Upside
Average
Price Target
43.86 USD
3% Upside
Highest
Price Target
45.15 USD
6% Upside
Taro Pharmaceutical Industries Ltd Competitors:
Price Targets
ORMP
Oramed Pharmaceuticals Inc
76% Upside
D
DPHARMA
Duopharma Biotech Bhd
28% Upside
SUPRIYA
Supriya Lifescience Ltd
3% Upside
MYX
Mayne Pharma Group Ltd
4% Upside
ORMP
Oramed Pharmaceuticals Inc
76% Upside
D
DPHARMA
Duopharma Biotech Bhd
28% Upside
SUPRIYA
Supriya Lifescience Ltd
3% Upside
MYX
Mayne Pharma Group Ltd
4% Upside
93M1
MPH Health Care AG
122% Upside
N
4516
Nippon Shinyaku Co Ltd
78% Upside
ZTS
Zoetis Inc
43% Upside
C
072020
Choong Ang Vaccine Laboratory
48% Upside

Revenue
Forecast

Revenue Estimate
Taro Pharmaceutical Industries Ltd

For the last 8 years the compound annual growth rate for Taro Pharmaceutical Industries Ltd's revenue is -5%. The projected CAGR for the next 1 year is 10%.

-5%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Taro Pharmaceutical Industries Ltd

For the last 8 years the compound annual growth rate for Taro Pharmaceutical Industries Ltd's operating income is -35%.

-35%
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Taro Pharmaceutical Industries Ltd

For the last 8 years the compound annual growth rate for Taro Pharmaceutical Industries Ltd's net income is -31%. The projected CAGR for the next 1 year is 66%.

-31%
Past Growth
66%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

See Also

Summary
TARO intrinsic value, competitors valuation, and company profile.
DCF Valuation
TARO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TARO stock valuation using valuation multiples.
Wall Street Estimates
TARO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TARO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TARO's stock price target?
Price Target
43.86 USD

According to Wall Street analysts, the average 1-year price target for TARO is 43.86 USD with a low forecast of 43.43 USD and a high forecast of 45.15 USD.

What is Taro Pharmaceutical Industries Ltd's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Taro Pharmaceutical Industries Ltd's revenue is -5%. The projected CAGR for the next 1 year is 10%.

What is Taro Pharmaceutical Industries Ltd's Net Income forecast?
Projected CAGR
66%

For the last 8 years the compound annual growth rate for Taro Pharmaceutical Industries Ltd's net income is -31%. The projected CAGR for the next 1 year is 66%.

ALPHA SPREAD
Join more than 132,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.